| Sep 2 |
Sanofi reports data from Phase III multiple sclerosis trials of tolebrutinib
|
| Sep 2 |
Sanofi drug misses primary endpoint in two trials for relapsing MS
|
| Sep 2 |
Sanofi Multiple Sclerosis Drug Delays Disability Progression in Trial
|
| Sep 2 |
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
|
| Aug 29 |
Sanofi: Better Buying Opportunities May Present Themselves In 2024
|
| Aug 28 |
Sanofi (SNY): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
|
| Aug 28 |
Five alternatives to Mag 7 stocks if you missed out on Nvidia
|
| Aug 27 |
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
|
| Aug 22 |
PAI Said to Rope in Sovereign Funds for Sanofi Consumer Unit Bid
|
| Aug 20 |
Kymera (KYMR) to Raise $225 Million Through Offering of Shares
|
